Important Notice: All ACC-related web platforms will be unavailable from Friday, May 10 until Tuesday, May 21 as part of system-wide upgrade to ACC’s digital infrastructure. Please plan accordingly. Mobile versions of the clinical apps remain available on the GooglePlay and Apple Store.
Terms of Service
Click the Terms tab at the bottom of the app before using the ASCVD Risk Estimator Plus (“the Product”) to read the full Terms of Service and License Agreement (the “Agreement”) which governs the use of the Product. The Agreement includes, among other detailed terms and conditions, certain disclaimers of warranties by the American College of Cardiology Foundation (“ACCF”) and requires the user to agree to release ACCF from any and all liability arising in connection with your use of the Product. By using the Product, you accept and agree to be bound by all of the terms and conditions set forth in the Agreement, including such disclaimers and releases. If you do not accept the terms and conditions of the Agreement, you may not proceed to use the Product. The Agreement is subject to change from time to time, and your continued use of the Product constitutes your acceptance of and agreement to be bound by any revised terms of the Agreement.
For Optimal Use:- Estimate patient’s 10-year ASCVD risk at an initial visit to establish a reference point.
- Forecast the potential impact of different interventions on patient risk.
- Reassess ASCVD risk at follow-up visits. Follow up risk incorporates change in risk factor levels over time and requires both initial and follow up values.
- Use the information above to help with clinician-patient discussions on risk and risk-lowering interventions.
See the “About” "About the App" screen in this app for a definition of terms and additional instructions.
xApp should be used for primary prevention patients (those without ASCVD) only.
For more information about the inputs and calculations used in
this app, see “Terms and Concepts” in the Resources tab
below.
**10-year risk for ASCVD is categorized as:
Low-risk
(<5%)
Borderline risk (5% to 7.4%)
Intermediate risk
(7.5% to 19.9%)
High risk (≥20%)
Indicates a
field required to calculate current 10-year ASCVD risk for
patients age 40-79 or Lifetime risk for patients age 20-59. Risk
will automatically calculate once these fields are populated.
Indicates
additional questions required to determine individualized patient
advice for patients age 40-79. Answering these questions in
addition to the indicated risk fields will activate the Therapy
Impact and Advice tabs.
Project Risk Reduction by Therapy
View Advice Summary for this Patient
Projected 10-Year ASCVD Risk
T1 15.3 % Stop Smoking, Add Statin Treatments
Add New Treatment Scenario
*Guidelines do not typically recommend aspirin therapy for patients with 10-year risk < 10%
*ACC/AHA Guidelines do not specify antihypertensive drug therapy for SBP<120 mmHg (<130 mmHg w/diabetes)
Projected 10-Year ASCVD Risk
T2 15.3 % Stop Smoking, Add Statin Treatments
Project a Different Therapy Combination
*Guidelines do not typically recommend aspirin therapy for patients with 10-year risk < 10%
*ACC/AHA Guidelines do not specify antihypertensive drug therapy for SBP<120 mmHg (<130 mmHg w/diabetes)
Projected 10-Year ASCVD Risk
T3 15.3 % Stop Smoking, Add Statin Treatments
Project a Different Therapy Combination
*Guidelines do not typically recommend aspirin therapy for patients with 10-year risk < 10%
*ACC/AHA Guidelines do not specify antihypertensive drug therapy for SBP<120 mmHg (<130 mmHg w/diabetes)
| Therapy(s) | Projected ASCVD Risk for this patient if Therapy Initiated |
|---|---|
| Statin* | |
| BP drug(s)** | |
| Stop smoking† | |
| Aspirinǂ | |
| Statin + Aspirin | |
| BP drug(s) + Aspirin | |
| Statin + BP drug(s) | |
| Statin + Stop smoking | |
| Stop smoking + Aspirin | |
| BP drug(s) + Stop smoking | |
| Statin + BP drug(s) + Aspirin | |
| BP drug(s) + Stop smoking + Aspirin | |
| Statin + BP drug(s) + Stop smoking | |
| Statin + Stop smoking + Aspirin | |
| Statin + BP drug(s) + Stop smoking + Aspirin |
**Start blood-pressure lowering medication if not currently taking, or add BP-lowering med (s) to patient’s existing regime.
†Stop smoking for two years
ǂStart or continue taking aspirin.
¶ NA = Not Applicable. Risk is not shown for therapy(s) that are not recommended. Guidelines do not recommend statin therapy for patients with 10-year ASCVD risk <5%. Guidelines do not typically recommend aspirin therapy for patients with 10-year risk <10%. ACC/AHA Guidelines do not specify antihypertensive drug therapy for SBP<120 mmHg (<130 mmHg w/diabetes)
**10-year risk for ASCVD is categorized as:
Low-risk
(<5%)
Borderline risk (5% to 7.4%)
Intermediate risk
(7.5% to 19.9%)
High risk (≥20%)
Visit Summary Below is a summary of patient’s risk, treatment options, and treatment advice based on the data provided.
Treatment Advice*
LDL-C Management (for this Patient)
Blood Pressure Management (for this Patient)
Tobacco Cessation (for this Patient)
Diabetes Mellitus Management (General)
Lifestyle Recommendations (General)
Aspirin Use Recommendations (for this Patient)
Immunization Practice (General)
Immunization Practice (for this Patient)
Therapy Safety Information (General)
ASCVD Risk Profile
- Actual Risk
- Projected Risk
- ASA = Start or continue taking aspirin
- BP = Start, add, or intensify blood pressure medication
- Ch = Manage cholesterol by starting or intensifying statin
- Sm = Stop smoking for at least 2 years
Inputs
Inputs
- Sex: Female
- Race: White
| Values | Previous | Current | Current |
|---|---|---|---|
| Age: | |||
| Total Cholesterol (mg/dL) (mmol/L) | 240 | ||
| HDL Cholesterol (mg/dL) (mmol/L) | |||
| LDL Cholesterol (mg/dL) (mmol/L) | |||
| Systolic Blood Pressure (mm Hg) | 98 | 140 | |
| Diastolic Blood Pressure (mm Hg) | 98 | 140 | |
| Diabetes: | |||
| Smoker: | |||
| Treatment for Hypertension: | Yes | ||
| Aspirin Therapy: | |||
| Statin: |
Because the primary use of these risk estimates is to facilitate the very important discussion regarding risk reduction through lifestyle change, the imprecision introduced is small enough to justify proceeding with lifestyle change counseling informed by these results.
*Disclaimer: The results and recommendations provided by this application are intended to inform but do not replace clinical judgment. Therapeutic options should be individualized and determined after discussion between the patient and their care provider.
Recommendations are designated with both a class of recommendation (COR) and a level of evidence (LOE). The class of recommendation indicates the strength of recommendation, encompassing the estimated magnitude and certainty of benefit in proportion to risk. The level of evidence rates the quality of scientific evidence supporting the intervention on the basis of the type, quantity, and consistency of data from clinical trials and other sources.
